secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0000950170-23-004858
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam Therapeutics reports Q4 2022 net loss of $38.3M; cash at $1.1B, runway into 2025
--------------------------------------------------------------------------------

- Net loss Q4 2022: $38.3M ($0.54/share) vs $64.7M ($0.95/share) in Q4 2021; full year net loss $289.1M ($4.13/share).
- Cash, cash equivalents and marketable securities $1.1B as of Dec 31, 2022, up from $965.6M at Dec 31, 2021.
- R&D expenses $86.3M in Q4 2022, down from $96.8M in Q4 2021; G&A expenses $22.7M vs $17.8M.
- Pipeline milestones: BEAM-101 sentinel cohort enrollment to finish 2023, BEAM-201 first patient dosing by mid-2023, BEAM-301 and BEAM-302 regulatory filings in late 2023/early 2024.
- North Carolina manufacturing facility expected to commence cGMP operations in late 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000095017023004858/0000950170-23-004858-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000095017023004858/beam-20230228.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-004858

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer